News and Milestones
March 18, 2025
CHO Plus Obtains U.S. Patent for Improved Production of Viral Vectors for Gene Therapy
Cell engineering technology will address unmet therapeutic needs by reducing cost and increasing availability of gene therapy
​
February 27, 2024
CHO Plus Strengthens and Expands Leadership Team with Key Appointment
Joseph Tarnowski joins CHO Plus as Chief Technology and Business Officer
​
February 4 – 8, 2024
Advancing Manufacture of Cell and Gene Therapies VIII
CHO Plus presented a poster describing our latest AAV production results (15-fold higher productivity; 2-fold higher capsid percent-full, to 55%) via engineered HEK-293 cells; we also presented results for our stably-transfected, inducible packaging cell line
(click here to see our poster presentations)
​
April 23 – 28, 2023
Cell Culture Engineering XVIII
CHO Plus presented three posters describing our cell engineering platform, our latest mAb production results (9.5 g/l; 117 pg/cell/day; 60-generation stability), and our latest AAV production results (9-fold higher productivity; 2-fold higher capsid percent-full)
(click here to see our poster presentations)
​
February 27 – March 2, 2023
New and updated results will be presented for high-productivity CHO cells for mAb production, including stability; also for high-productivity HEK cells for AAV production
Oral presentation on March 2: Novel Cell Engineering Platform for Creating High-Productivity Cells for Therapeutic Protein Production, and for Other Purposes.
​
August 15 - 18, 2022
CHO Plus announces 9.5 g/l human mAb productivity in CHO cell cultures
Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures
​
June 26 - 29, 2022
Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures
​
August 24, 2021
CHO Plus Announces Acceptance into BLUE KNIGHT™
CHO Plus’s participation in this joint initiative is another step toward commercializing its patented cell engineering technology
December 21, 2020
CHO Plus moves to Johnson & Johnson Innovation - JLABS @ South San Francisco
​
December 1, 2020
CHO Plus Announces Research Collaboration Agreement with Janssen
Collaboration will move CHO Plus closer to commercializing its patented cell engineering technology
​
June 25, 2019
Key US patent issued to CHO Plus. Patent No. US 10,329,594:
Cell Lines for High Level Production of Protein-Based Pharmaceuticals
​
June 1, 2019
James Panek joins CHO Plus as Chief Operating Officer. Jim is an experienced pharma executive who held such positions as Senior VP, Product Operations at Genentech.
​
March 26, 2016
Presented company to investors at EPPICon 2016, Burlingame, CA
First place in Speed Pitch session
March 2, 2016
Presented company to investors at Venture Summit - West, Mountain View, CA
October 2015
Patent application filed: Identifying high transcription areas in cell genomes to enhance production of biopharmaceuticals
September 2015
Patent application filed: Cell Lines for High Level Production of Protein-based Pharmaceuticals
June 2015
CHO Plus genetically engineered CHO cells shown to have 4.5-fold higher productivity than parent CHO-K1 cell line
September 2014
Research operations commence at qb3@953 in San Francisco
March 2014
CHO Plus incorporates in Delaware